Long Focus Capital Management’s Aura Biosciences AURA Stock Holding History

Long Focus Capital Management’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.3M	Buy	5,119,582 +500,000	+11%	+$3.58M	0.93%	30
2026 Q1	$30.9M	Hold	4,619,582	–	–	0.81%	35
2025 Q4	$25.2M	Hold	4,619,582	–	–	0.66%	41
2025 Q3	$28.5M	Hold	4,619,582	–	–	0.94%	30
2025 Q2	$28.9M	Buy	4,619,582 +1,300,000	+39%	+$7.6M	1.09%	25
2025 Q1	$19.5M	Buy	3,319,582 +781,808	+31%	+$5.91M	0.65%	38
2024 Q4	$20.9M	Buy	2,537,774 +1,404,228	+124%	+$13.2M	0.68%	28
2024 Q3	$10.1M	Buy	1,133,546 +76,358	+7%	+$655K	0.35%	44
2024 Q2	$7.99M	Buy	1,057,188 +561,766	+113%	+$4.11M	0.31%	48
2024 Q1	$3.89M	Buy	495,422 +155,000	+46%	+$1.28M	0.2%	65
2023 Q4	$3.02M	Buy	340,422 +145,247	+74%	+$1.23M	0.1%	71
2023 Q3	$1.75M	Buy	195,175 +15,000	+8%	+$161K	0.06%	73
2023 Q2	$2.23M	Buy	180,175 +8,798	+5%	+$94K	0.1%	67
2023 Q1	$1.59M	Buy	+171,377	New	+$1.78M	0.09%	77

Other funds holding AURA

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Long Focus Capital Management's AURA Position: Q2 2026 in Review

Long Focus Capital Management increased its Aura Biosciences (AURA) stake by 11% in Q2 2026, buying an estimated $3.58M and bringing the position to 5,119,582 shares worth $36.3M. The position accounts for 0.93% of the portfolio, ranked #30.

Long Focus Capital Management first reported a position in AURA in Q1 2023 and has held it in 14 quarters since. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

Long Focus Capital Management held 5,119,582 shares of Aura Biosciences worth $36.3M as of Q2 2026.
Long Focus Capital Management bought 500,000 Aura Biosciences shares in Q2 2026, an estimated $3.58M.
Aura Biosciences made up 0.93% of Long Focus Capital Management's portfolio in Q2 2026, its #30 holding.
Long Focus Capital Management first reported a position in Aura Biosciences in Q1 2023 and has held it in 14 quarters since.
147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Long Focus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.